EHA 2019: New therapeutic target in T-cell Acute Lymphoblastic Leukaemia

Etienne De Braekeller | EHA 2019 | Juni 17, 2019

Föreläsare: Etienne De Braekeller

Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer. Activating mutations in the NOTCH1gene are found in more than 60% of cases of T-cell Acute Lymphoblastic leukaemia (T-ALL) and are being targeted therapeutically with compounds such as γ-secretase inhibitors (GSIs) and Notch inhibiting antibodies (mAbs).

In this MEDtalk Etienne De Braekeleer present the propose that the intracellular domain of NOTCH1 activates NADK to enhance the production NADP+/NADPH, a function required to support it proliferative effects. This frames NADK as a putative novel therapeutic vulnerability of NOTCH1-driven T-ALL and potentially other NOTCH1-driven cancers